UFP Technologies, Inc. (UFPT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and UFP Technologies published the results on November 3, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. UFP Technologies reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• UFP Technologies reports in thousands of dollars; figures here are converted to millions. It has a single operating and reportable segment; the Medical and Non-medical split comes from the 10-Q.
• UFP Technologies bought CI Medical (Creative Imprints, Inc.), a medical pad-printing business in Norton, Massachusetts, on August 25, 2026 for $6.9 million in cash. Acquired operations added $725 thousand of Q3 2026 sales.

Source: UFP Technologies Q3 2026 results, November 3, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How UFP Technologies splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• UFP Technologies's Medical revenue was $160 million in Q3 2026, up 13% from $142 million in Q3 2025, 93% of total revenue.
• UFP Technologies's Non-medical revenue was $12.3 million in Q3 2026, flat on $12.2 million in Q3 2025, 7% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for UFP Technologies's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 3, 2026

UFP Technologies is a contract development and manufacturing organization for single-use and single-patient medical devices and components, used in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods and orthopedic implants. Medical customers brought in $160.2 million of its $172.4 million of Q3 2026 net sales, 92.9%, and Non-medical customers $12.3 million. (UFP Technologies Form 10-K, 2025, Feb 27, 2026; UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026)

Net sales rose 11.6% from $154.6 million a year earlier. UFP Technologies attributed the increase largely to growth in its Patients Beds and Handling, Cardiovascular, Infection Control and Orthopedics sub-markets. Organic sales growth was 11.1%; acquired operations contributed $725 thousand. Its CEO said MedTech sales grew 12.5%. (UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026; UFP Technologies Q3 2026 release, Nov 3, 2026)

Two customers dominate UFP Technologies' sales. They accounted for approximately 24.8% and 21.8% of net sales in Q3 2026, against 27.1% and 17.1% a year earlier. The 10-K names Intuitive Surgical SARL as its largest customer, and the supply agreements with its two largest customers are listed as a risk. (UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026; UFP Technologies Form 10-K, 2025, Feb 27, 2026)

Almost all of UFP Technologies' revenue is product sales: $169.0 million in the quarter, with tooling and machinery at $1.5 million and engineering services at $2.0 million. Sales shipped to customers outside the United States were approximately 17.1% of net sales, up from 15.0% a year earlier. (UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026)

UFP Technologies' GAAP diluted EPS was $2.64 in Q3 2026 and adjusted EPS $2.88, against $2.11 and $2.39 a year earlier. The adjusted figure adds back amortization of intangible assets ($2.5 million), acquisition costs and the gain or loss on disposal of fixed assets, net of $645 thousand of taxes on those adjustments. (UFP Technologies Q3 2026 release, Nov 3, 2026)

Net income rose 25.8% to $20.6 million, faster than sales, because gross margin increased to 29.4% from 27.7% and net interest expense fell to $1.5 million from $2.4 million. UFP Technologies credited the margin gain primarily to operating efficiencies and to spreading strong organic sales growth over fixed overhead. SG&A rose 21.4% to $23.2 million. (UFP Technologies Q3 2026 release, Nov 3, 2026; UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026)

The tax rate was approximately 21.1% of pre-tax income, down from 22.2%, which UFP Technologies said was largely due to higher anticipated income from foreign operations. Weighted average diluted shares were 7,806 thousand, against 7,780 thousand a year earlier. (UFP Technologies Form 10-Q, Q3 2026, Nov 6, 2026; UFP Technologies Q3 2026 release, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

UFP Technologies does not publish a numeric revenue or earnings outlook in its release. Its CEO said the company has invested in additional capacity at DAS Medical to support double-digit growth, that it is working to expand its credit facility, and that scheduled program transfers to the Dominican Republic and margin improvement at AJR remain behind plan. (UFP Technologies Q3 2026 release, Nov 3, 2026)

A consensus figure is the average of the models published by the analysts who cover UFP Technologies, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones UFP Technologies's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning UFPT is on is UFPT a buy or a sell?, what analysts expect next is on the UFPT forecast, and what the company does is on the UFP Technologies, Inc. (UFPT) stock page.

Every number on this page can be traced to a document UFP Technologies published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.